Skip to main content

Thompson Elizabeth H.Z.'s Form 4 filing

Acadia Pharmaceuticals Inc (ACAD) · filed Jul 31, 2026

Accession no.
0001861477-26-000005
Filed
Jul 31, 2026, 6:00 PM ET
Trade date
Jul 29-30, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $432.7K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Thompson Elizabeth H.Z.CIK 0001861477Officer (EVP, Head of Research & Dev)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 29, 2026Common StockMOption exerciseAcquired+32,272–F1–35,552Direct
Jul 30, 2026Common StockSSaleDisposed−16,508$26.13−$431,354.0419,044Direct
Jul 30, 2026Common StockSSaleDisposed−50$26.17−$1,308.518,994Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 29, 2026Common StockMOption exerciseDisposed−32,272$0.00$032,272Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)